Celltrion Inc
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- -
- Established
- 1999-01-01
- Employees
- -
- Market Cap
- $31.9B
- Website
- http://www.celltrion.com/
A Phase 3 Study to Evaluate Efficacy & Safety of Subcutaneous CT-P13 in Patients with Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 189
- Registration Number
- NCT06738719
To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 200
- Registration Number
- NCT06687928
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Psoriasis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 375
- Registration Number
- NCT06630559
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 582
- Registration Number
- NCT06571591
- Locations
- 🇰🇷
Celltrion, Incheon, Korea, Republic of
Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 154
- Registration Number
- NCT06037395
- Locations
- 🇰🇷
Chungnam National University Hospital, Daejeon, Jung-gu, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam, Bundang-gu, Korea, Republic of
A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy Volunteers
- First Posted Date
- 2023-08-15
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 50
- Registration Number
- NCT05993806
- Locations
- 🇰🇷
H plus Yangji Hospital, Seoul, Korea, Republic of
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 512
- Registration Number
- NCT05906992
- Locations
- 🇵🇱
CT-P53 3.1 investigational site, Poznań, Poland
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 864
- Registration Number
- NCT05866614
- Locations
- 🇫🇷
CHU Purpan Hôpital Pierre Paul Riquet, Toulouse, France
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 30
- Registration Number
- NCT05725434
Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- Celltrion
- Target Recruit Count
- 268
- Registration Number
- NCT05617183
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
© Copyright 2024. All Rights Reserved by MedPath